--- title: "Intercure (INCR) stock listing, news and investor profile" url: "https://aibio.space/companies/intercure/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Intercure Ltd. (NASDAQ: INCR), United States. Listing facts, related biotech companies and news on aibio.space." --- INCR Intercure Ltd. NASDAQ · United States # Intercure (INCR) news Intercure Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker INCR, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest Intercure news We have not published a story on Intercure yet. When there is news, it will appear here. ## Intercure at a glance - **Ticker**: INCR - **Listing**: NASDAQ - **Country**: United States - **Cash, Dec 31, 2024**: ₪78.7 million ### Related companies - [COOPER COMPANIES, INC.](https://aibio.space/companies/cooper-companies/) NASDAQ: COO - [Sight Sciences](https://aibio.space/companies/sight-sciences/) NASDAQ: SGHT - [ARTIVION, INC.](https://aibio.space/companies/artivion/) NYSE: AORT - [VITASPRING BIOMEDICAL CO. LTD.](https://aibio.space/companies/vitaspring-biomedical/) OTC: VSBC - [Bio Essence](https://aibio.space/companies/bio-essence/) OTC: BIOE - [One World Products](https://aibio.space/companies/one-world-products/) OTC: OWPC - [Beyond Air](https://aibio.space/companies/beyond-air/) NASDAQ: XAIR - [Adagio Medical Holdings](https://aibio.space/companies/adagio-medical/) NASDAQ: ADGM ### Also on NASDAQ - [IM Cannabis](https://aibio.space/companies/im-cannabis/) IMCC - [ENDRA Life Sciences](https://aibio.space/companies/endra-life-sciences/) NDRA - [Electra Therapeutics](https://aibio.space/companies/electra-therapeutics/) ETRA - [Annexon](https://aibio.space/companies/annexon/) ANNX - [HeartBeam](https://aibio.space/companies/heartbeam/) BEATW - [Absci](https://aibio.space/companies/absci/) ABSI ## What Intercure does InterCure Ltd. is an Israeli company that produces, manufactures and distributes pharmaceutical-grade cannabis and cannabis-based products for medical use, mainly through its subsidiary Canndoc. It states that it has been a leader in licensed production and distribution of medical cannabis in Israel for more than 18 years. Its products are manufactured using processes certified to IMCA standards, including IMC-GMP, and tested by IMCA-certified laboratories. In Israel it distributes products through licensed retail pharmacy locations, and it has agreements to establish joint ventures and supply and distribution arrangements in the European Union and Canada, with a stated plan to distribute under the CANNDOC brand. None of its products had been distributed through those partnerships as of the date of the report. Its Southern Facility in Nir Oz was severely damaged in October 2023 and is being restored, and its Northern Facility can produce up to three tons of pharmaceutical-grade cannabis per year. The company says it does not produce or distribute cannabis in the United States, and that its biomed investment segment is not material to its operations. | Product or program | What it is | Stage | |---|---|---| | Pharmaceutical-grade cannabis products (CANNDOC brand) | Medical cannabis products manufactured to IMCA and IMC-GMP standards | distributed through licensed pharmacies in Israel | | Cannabis production capacity (Southern and Northern Facilities) | Cultivation and processing sites producing cannabis for medical use | Southern Facility being restored | Summarised from the company's [20-F filed Apr 30, 2026](https://www.sec.gov/Archives/edgar/data/1857030/000149315226020743/form20-f.htm). ## Intercure annual financials | Line | FY2024 | FY2023 | |---|---|---| | Revenue | [₪238.8 million](https://www.sec.gov/Archives/edgar/data/1857030/000164117225007971/) | [₪355.6 million](https://www.sec.gov/Archives/edgar/data/1857030/000164117225007971/) | | Research and development | [₪414,000](https://www.sec.gov/Archives/edgar/data/1857030/000164117225007971/) | [₪388,000](https://www.sec.gov/Archives/edgar/data/1857030/000164117225007971/) | | Net income (loss) | [-₪72.8 million](https://www.sec.gov/Archives/edgar/data/1857030/000164117225007971/) | [-₪63.5 million](https://www.sec.gov/Archives/edgar/data/1857030/000164117225007971/) | | Cash from operations | [-₪66.9 million](https://www.sec.gov/Archives/edgar/data/1857030/000164117225007971/) | [-₪53.6 million](https://www.sec.gov/Archives/edgar/data/1857030/000164117225007971/) | | Cash and equivalents | [₪78.3 million](https://www.sec.gov/Archives/edgar/data/1857030/000164117225007971/) | [₪101.1 million](https://www.sec.gov/Archives/edgar/data/1857030/000164117225007971/) | | Short-term investments | [₪333,000](https://www.sec.gov/Archives/edgar/data/1857030/000164117225007971/) | [₪187,000](https://www.sec.gov/Archives/edgar/data/1857030/000149315224017348/) | Latest balance sheet, Dec 31, 2024 (20-F): cash and equivalents ₪78.3 million, plus short-term investments of ₪333,000, ₪78.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Intercure What is the ticker symbol of Intercure? Intercure Ltd. trades under the ticker INCR on NASDAQ. Where is Intercure listed? Intercure Ltd. is listed on NASDAQ. Which country or territory is Intercure listed under? Our directory records Intercure Ltd. under United States. Does aibio.space cover Intercure? aibio.space lists Intercure Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. What does Intercure develop? InterCure Ltd. is an Israeli company that produces, manufactures and distributes pharmaceutical-grade cannabis and cannabis-based products for medical use, mainly through its subsidiary Canndoc. It states that it has been a leader in licensed production and distribution of medical cannabis in Israel for more than 18 years. What is Pharmaceutical-grade cannabis products (CANNDOC brand) from Intercure? Pharmaceutical-grade cannabis products (CANNDOC brand): Medical cannabis products manufactured to IMCA and IMC-GMP standards Stage: distributed through licensed pharmacies in Israel. What is Cannabis production capacity (Southern and Northern Facilities) from Intercure? Cannabis production capacity (Southern and Northern Facilities): Cultivation and processing sites producing cannabis for medical use Stage: Southern Facility being restored. ## Investor discussion: Intercure Members talk about Intercure (INCR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Intercure, newest first. Each line links the filing it comes from. 1. 2026-09-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1857030/000149315226041771/ex99-1.htm) 2. 2026-08-26 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1857030/000149315226040235/form6-k.htm) 3. 2026-07-22 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1857030/000149315226034228/ex99-1.htm) 4. 2026-06-22 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1857030/000149315226029516/ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:INCR on TradingView](https://www.tradingview.com/symbols/NASDAQ-INCR/). ## Listing details Intercure Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker INCR, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Intercure Ltd. - **Ticker**: INCR - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/intercure/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Intercure (INCR) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/intercure/